This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Prognosis/ Outcomes  • Neoplasms of Head & Neck  • Pathology of Head & Neck  • Alert me on articles by topic

Stephen Lo, BMedSc, MBA, MRCS, DLO; Wai-Kuen Ho, FACS, FRCS(Edin); William I. Wei, MS, FACS, FRCS, FRCS(Edin)

Arch Otolaryngol Head Neck Surg. 2004;130:770-772.

Objective  To evaluate the current clinical practice of follow-up and the outcomes of patients with raised Epstein-Barr virus (EBV) antibody levels but without pathological evidence of nasopharyngeal carcinoma (NPC) for a possible risk of developing NPC in the future.

Design  Retrospective review of prospectively collected database.

Setting  Tertiary referral otorhinolaryngology center.

Patients  The study population comprised 66 patients (27 male and 39 female; median age, 43.5 [range, 9-78] years) who presented in 1997 with a positive EBV IgA viral capsid antigen titer but a negative nasopharyngeal biopsy result.

Main Outcome Measures  The detection of NPC and EBV seroconversion rate.

Results  Of the 66 patients studied, 14 had a positive family history of NPC. Fourteen patients (27%) were excluded because of loss of contact or refusal of follow-up. The median follow-up period of the remaining 52 patients was 54.5 months (range, 12-64 months). Of these 52 patients, 39 (75%) had initial nasendoscopic finding described as completely normal. During the follow-up period, NPC was diagnosed in 1 patient (2%) 18 months after first biopsy. The initial nasendoscopy and histological findings in this patient were normal despite the patient having a raised EBV IgA VCA titer of 1:640. Overall, the EBV serologic status of 36 patients (69%) reverted to normal within the studied period (median interval of 54.5 [range, 12-64] months).

Conclusions  In the median follow-up period of 54.5 months, only 1 patient (2%) developed NPC. A significant proportion of the patients seroconverted back to normal, none of whom developed NPC.

From the Department of Otorhinolaryngology–Head & Neck Surgery, St George's Hospital Medical School, University of London, London, England (Dr Lo); Division of Otorhinolaryngology–Head & Neck Surgery, Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong (Dr Ho and Dr Wei). The authors have no relevant financial interest in this article.